Phosphonate-modified GdDTPA complexes. II. Evaluation in a rat myocardial infarct model.
The localization of 1-hydroxy-3-aminopropane-1,1-diphosphonate-modified GdDTPA (GdDTPA-HPDP) and 4-amino-butane-1,1-diphosphonate-modified GdDTPA (GdDTPA-BDP) in (1) normal and (2) infarcted rat hearts has been measured. The phosphonate-modified agents are preferentially retained in infarcted myocardium. The ratio of GdDTPA-HPDP accumulated in whole infarcted heart to that detected in normal heart is 15 at 2 hours after injecting a dose of 50 to 100 mumol/kg; the ratio is 2 for GdDTPA. At these doses, significant changes are detected in the tissue relaxation rates. An average relaxivity of 11.2 (mmol-sec)-1 is calculated for the agent in the infarcted whole heart. GdDTPA-BDP, in comparison, displayed prolonged blood retention. The result is a low diseased-to-normal heart ratio (approximately 2) at 2 hours, making this agent less attractive as a contrast agent.
Adzamli
I K
IK
Department of Radiology, Harvard Medical School, Boston, Massachusetts.
Johnson
D
D
Blau
M
M
D000818:Animals; D003287:Contrast Media / Q000493:pharmacokinetics*; D004164:Diphosphonates / Q000493:pharmacokinetics*; D005069:Evaluation Studies as Topic; D019786:Gadolinium DTPA; D008279:Magnetic Resonance Imaging; D008297:Male; D009203:Myocardial Infarction / Q000175:diagnosis* / Q000378:metabolism; D009206:Myocardium / Q000378:metabolism; D004369:Pentetic Acid / Q000493:pharmacokinetics*; D051381:Rats; D011919:Rats, Inbred Strains; D014018:Tissue Distribution
D003287:Contrast Media; D004164:Diphosphonates; C069494:DTPA-1-hydroxy-3-aminopropane-1,1-diphosphonate; C069495:DTPA-4-aminobutane-1,1-diphosphonate; D004369:Pentetic Acid; D019786:Gadolinium DTPA